<?xml version="1.0" encoding="UTF-8" standalone="yes"?><drugRecordsOutput><serviceExecutionTime>362</serviceExecutionTime><Drug id="28262"><DrugName>PD-0183812</DrugName><DrugSynonyms><Name><Value>PD-0183812</Value><Types><Type>Research Code</Type></Types></Name><Name><Value>211247-24-4</Value><Types><Type>CAS RN</Type></Types></Name></DrugSynonyms><CompanyOriginator id="18767">Pfizer Inc</CompanyOriginator><CompaniesSecondary><Company id="18683">Onyx Pharmaceuticals Inc</Company><Company id="18767">Pfizer Inc</Company><Company id="20805">Parke-Davis &amp; Co</Company></CompaniesSecondary><CrossReferences><SourceEntity id="28262" type="Drug"><TargetEntity id="287329" type="siDrug">PD-0183812</TargetEntity></SourceEntity><SourceEntity id="18683" type="Company"><TargetEntity id="4295907479" type="organizationId">Onyx Pharmaceuticals Inc</TargetEntity></SourceEntity><SourceEntity id="18767" type="Company"><TargetEntity id="4295904722" type="organizationId">Pfizer Inc</TargetEntity></SourceEntity><SourceEntity id="20805" type="Company"><TargetEntity id="5000120321" type="organizationId">Parke Davis &amp; Company LLC</TargetEntity></SourceEntity><SourceEntity id="289" type="ciIndication"><TargetEntity id="10038916" type="MEDDRA"></TargetEntity><TargetEntity id="D012175" type="MeSH"></TargetEntity><TargetEntity id="790" type="ORPHANET"></TargetEntity><TargetEntity id="-83667607" type="omicsDisease"></TargetEntity><TargetEntity id="793" type="siCondition"></TargetEntity></SourceEntity><SourceEntity id="651" type="ciIndication"><TargetEntity id="576" type="siCondition"></TargetEntity></SourceEntity><SourceEntity id="4314" type="Action"><TargetEntity id="984" type="Mechanism">CDK4 Inhibitors</TargetEntity><TargetEntity id="3181" type="Mechanism">CDK4/Cyclin D Inhibitors</TargetEntity><TargetEntity id="3006" type="Mechanism">CDK4/Cyclin D3 Inhibitors</TargetEntity><TargetEntity id="1721" type="Mechanism">CDK4/Cyclin D1 Inhibitors</TargetEntity><TargetEntity id="3182" type="Mechanism">CDK4/Cyclin D2 Inhibitors</TargetEntity></SourceEntity><SourceEntity id="PTGT-00528" type="ciTarget"><TargetEntity id="89421011710193" type="siTarget">Cyclin-dependent kinase 4</TargetEntity><TargetEntity id="135" type="omicsTarget"></TargetEntity></SourceEntity></CrossReferences><PhaseHighest id="DX">Discontinued</PhaseHighest><PhaseTerminated id="DR">Discovery</PhaseTerminated><IndicationsSecondary><Indication id="289">Retinoblastoma</Indication><Indication id="651">Cancer</Indication></IndicationsSecondary><ActionsPrimary><Action id="4314">Cyclin-dependent kinase-4 inhibitor</Action></ActionsPrimary><ActionsSecondary><Action id="62255">Anticancer protein kinase inhibitor</Action><Action id="767">Cell cycle inhibitor</Action></ActionsSecondary><Technologies><Technology id="762">Small molecule therapeutic</Technology></Technologies><LastModificationDate>2017-08-18T11:29:52.000Z</LastModificationDate><ChangeDateLast>2008-12-09T14:42:24.000Z</ChangeDateLast><AddedDate>2000-04-13T17:12:27.000Z</AddedDate><DevelopmentProfile><Summary><displayLabel>Summary</displayLabel><value>&lt;Summary&gt;&lt;para&gt;&lt;ulink linkID="28262" linkType="Drug"&gt;PD-0183812&lt;/ulink&gt;, a potent and selective CDK4/cyclinD1 inhibitor from a series of [2,3-d] pyridopyramidines, was being investigated by Pfizer (formerly by Parke-Davis) and Onyx as a potential treatment for Rb-positive tumors [&lt;ulink linkID="362425" linkType="reference"&gt;362425&lt;/ulink&gt;]. However,  by August 2001, Pfizer was advancing the lead candidate, &lt;ulink linkID="10271" linkType="Drug"&gt;PD-332991&lt;/ulink&gt;(qv), and was no longer investigating other compounds in the series  [&lt;ulink linkID="490076" linkType="Reference"&gt;490076&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In in vitro studies, &lt;ulink linkID="28262" linkType="Drug"&gt;PD-0183812&lt;/ulink&gt; inhibited purified CDK4 with an IC50 value of 0.008 microM but showed 26- and &amp;gt; 5000-fold less activity against CDK2/cyclinA and CDC2/cyclinB, respectively. Flow cytometry analysis showed that Rb-positive tumor cells were arrested in G1 after treatment with &lt;ulink linkID="28262" linkType="Drug"&gt;PD-0183812&lt;/ulink&gt; whereas Rb-negative cells continued to cycle [&lt;ulink linkID="362425" linkType="reference"&gt;362425&lt;/ulink&gt;].&lt;/para&gt;&lt;/Summary&gt;</value></Summary></DevelopmentProfile><IDdbDevelopmentStatus><DevelopmentStatusCurrent><Company id="18767">Pfizer Inc</Company><Country id="US">US</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="3">Pipeline Prioritization</DiscontinuedReason><Indication id="289">Retinoblastoma</Indication><StatusDate>2001-08-31T00:00:00.000Z</StatusDate><Source id="490076" type="CORPORATE"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="18767">Pfizer Inc</Company><Country id="US">US</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="3">Pipeline Prioritization</DiscontinuedReason><Indication id="651">Cancer</Indication><StatusDate>2001-08-31T00:00:00.000Z</StatusDate><Source id="490076" type="CORPORATE"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="18683">Onyx Pharmaceuticals Inc</Company><Country id="US">US</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="3">Pipeline Prioritization</DiscontinuedReason><Indication id="289">Retinoblastoma</Indication><StatusDate>2001-08-31T00:00:00.000Z</StatusDate><Source id="490076" type="CORPORATE"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="18683">Onyx Pharmaceuticals Inc</Company><Country id="US">US</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="3">Pipeline Prioritization</DiscontinuedReason><Indication id="651">Cancer</Indication><StatusDate>2001-08-31T00:00:00.000Z</StatusDate><Source id="490076" type="CORPORATE"/></DevelopmentStatusCurrent><DevelopmentStatusHistoric><Company id="20805">Parke-Davis &amp; Co</Company><Country id="US">US</Country><DevelopmentStatus id="DR" sortOrder="7">Discovery</DevelopmentStatus><Indication id="651">Cancer</Indication><StatusDate>2000-04-13T00:00:00.000Z</StatusDate><Source id="362425" type="SERIAL"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="20805">Parke-Davis &amp; Co</Company><Country id="US">US</Country><DevelopmentStatus id="DR" sortOrder="7">Discovery</DevelopmentStatus><Indication id="289">Retinoblastoma</Indication><StatusDate>2000-04-13T00:00:00.000Z</StatusDate><Source id="362425" type="SERIAL"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="18683">Onyx Pharmaceuticals Inc</Company><Country id="US">US</Country><DevelopmentStatus id="DR" sortOrder="7">Discovery</DevelopmentStatus><Indication id="651">Cancer</Indication><StatusDate>2000-04-13T00:00:00.000Z</StatusDate><Source id="362425" type="SERIAL"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="18683">Onyx Pharmaceuticals Inc</Company><Country id="US">US</Country><DevelopmentStatus id="DR" sortOrder="7">Discovery</DevelopmentStatus><Indication id="289">Retinoblastoma</Indication><StatusDate>2000-04-13T00:00:00.000Z</StatusDate><Source id="362425" type="SERIAL"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="18767">Pfizer Inc</Company><Country id="US">US</Country><DevelopmentStatus id="DR" sortOrder="7">Discovery</DevelopmentStatus><Indication id="651">Cancer</Indication><StatusDate>2000-06-29T00:00:00.000Z</StatusDate><Source id="371470" type="PR"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="18767">Pfizer Inc</Company><Country id="US">US</Country><DevelopmentStatus id="DR" sortOrder="7">Discovery</DevelopmentStatus><Indication id="289">Retinoblastoma</Indication><StatusDate>2000-06-29T00:00:00.000Z</StatusDate><Source id="371470" type="PR"/></DevelopmentStatusHistoric></IDdbDevelopmentStatus><Targets><Target id="PTGT-00528"><Name>Cyclin-dependent kinase-4</Name><SwissprotNumbers><Swissprot>P11802</Swissprot><Swissprot>P30285</Swissprot><Swissprot>P35426</Swissprot><Swissprot>P79432</Swissprot><Swissprot>Q91727</Swissprot></SwissprotNumbers></Target></Targets><ReasonsForUpdate><ReasonForUpdate><Reason>Development Status Updated</Reason><Description>One or more development status entries have been updated</Description></ReasonForUpdate></ReasonsForUpdate><CountsByCompanies><Company><Company id="14109">Amgen Inc</Company><CountAsPrincipalActive>0</CountAsPrincipalActive><CountAsPrincipalInactive>0</CountAsPrincipalInactive><CountAsPartnerActive>0</CountAsPartnerActive><CountAsPartnerInactive>0</CountAsPartnerInactive><CountTotal>1</CountTotal></Company><Company><Company id="18767">Pfizer Inc</Company><CountAsPrincipalActive>1</CountAsPrincipalActive><CountAsPrincipalInactive>0</CountAsPrincipalInactive><CountAsPartnerActive>1</CountAsPartnerActive><CountAsPartnerInactive>0</CountAsPartnerInactive><CountTotal>1</CountTotal></Company></CountsByCompanies><CountsByTypes><Type><Type sortOrder="3">Drug - Early Research/Development</Type><CountActive>1</CountActive><CountInactive>0</CountInactive><CountTotal>1</CountTotal></Type></CountsByTypes><StructureSmiles><Smiles>c1cc(ccc1Nc2ncc3ccc(=O)n(c3n2)C4CC5CCC4C5)N6CCC(CC6)CCCO</Smiles></StructureSmiles><Deals><Deal id="114929" title="Onyx and Warner-Lambert to research cell cycle regulation in anticancer therapeutics  "/></Deals><hasSWOTs>N</hasSWOTs></Drug></drugRecordsOutput>